Angiogenèse
Les inhibiteurs de l'angiogenèse sont des composés qui interfèrent avec la formation de nouveaux vaisseaux sanguins, un processus crucial dans la croissance et la métastase des cancers. En inhibant l'angiogenèse, ces composés peuvent restreindre l'apport sanguin aux tumeurs, ralentissant ou arrêtant leur croissance. Les inhibiteurs de l'angiogenèse sont essentiels dans la recherche sur le cancer et le développement thérapeutique, offrant des informations sur les mécanismes de progression tumorale et proposant des traitements potentiels pour le cancer et d'autres maladies liées à l'angiogenèse. Chez CymitQuimica, nous offrons une large gamme d'inhibiteurs de l'angiogenèse de haute qualité pour soutenir vos recherches en oncologie et biologie vasculaire.
Sous-catégories appartenant à la catégorie "Angiogenèse"
- BTK(167 produits)
- Bcr-Abl(118 produits)
- EGFR(581 produits)
- FAK(72 produits)
- FLT(86 produits)
- Récepteur du facteur de croissance des fibroblastes (FGFR)(180 produits)
- JAK(243 produits)
- PDGFR(129 produits)
- RAAS(89 produits)
- Src(82 produits)
- Syk(37 produits)
- Thrombine(57 produits)
- VDA(2 produits)
- VEGFR(242 produits)
Affichez 6 plus de sous-catégories
2387 produits trouvés pour "Angiogenèse"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
EGFR-IN-67
CAS :EGFR-IN-67 (Compound 7d) is a potent inhibitor of EGFR with anticancer activity (IC 50 = 0.34 μM) [1].Formule :C18H17N3SCouleur et forme :SolidMasse moléculaire :307.41RO9021
CAS :RO9021 is an orally bioavailable, novel ATP-competitive SYK inhibitor (average IC50: 5.6 nM).Formule :C18H25N7ODegré de pureté :99.90%Couleur et forme :SolidMasse moléculaire :355.44BPIQ-II (hydrochloride)
CAS :BPIQ-II, a selective EGFR inhibitor with an IC50 of 8 pM, targets ATP sites and halts EGF signals inside cells.Formule :C15H11BrClN5Couleur et forme :SolidMasse moléculaire :376.64INCB16562
CAS :INCB16562: oral JAK1/2 inhibitor, halts IL-6/STAT3 in myeloma cells, boosts drug efficacy, stunts myeloma in mice.Formule :C19H11Cl2N5Couleur et forme :SolidMasse moléculaire :380.23PDGFRα/FLT3-ITD-IN-2
CAS :PDGFRα/FLT3-ITD-IN-2 is a potent inhibitor of PDGFRα (IC50>20 μM) and FLT3 (IC50: 0.004 μM).Formule :C28H41N9OCouleur et forme :SolidMasse moléculaire :519.68FIIN-4
CAS :FIIN-4 is a covalent inhibitor of FGFR and can be used in studies about metastatic breast cancer.Formule :C35H38N8O4Degré de pureté :99.99%Couleur et forme :SolidMasse moléculaire :634.73JAK-IN-20
CAS :JAK-IN-20: potent oral JAK1,2,3 inhibitor with IC50s 7, 5, 14 nM respectively, good pharmacokinetics, anti-inflammatory in vivo.Formule :C28H30FN7O2Couleur et forme :SolidMasse moléculaire :515.58Nuvenzepine
CAS :Nuvenzepine is an antagonist of mAChR. It has the potential for gastrospasm treatment.Formule :C19H20N4O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :336.39CHMFL-ABL-053
CAS :CHMFL-ABL-053: potent, selective BCR-ABL/SRC/p38 inhibitor (IC50: 70/90/62 nM). Orally available, potential CML drug.Formule :C28H26F3N7O2Couleur et forme :SolidMasse moléculaire :549.55Peficitinib hydrochloride
CAS :Peficitinib HCl (ASP015K) is an oral JAK inhibitor with IC50s: JAK1 (3.9 nM), JAK2 (5.0 nM), JAK3 (0.7 nM), Tyk2 (4.8 nM).Formule :C18H23ClN4O2Couleur et forme :SolidMasse moléculaire :362.86VEGFR-2-IN-30
VEGFR-2-IN-30: VEGFR-2 inhibitor, IC50 66 nM; blocks PDGFR, EGFR & FGFR1; halts cancer cell cycle, induces apoptosis.Formule :C28H23ClN6O4S2Couleur et forme :SolidMasse moléculaire :607.1BTK inhibitor 10
CAS :BTK inhibitor 10, an oral drug from patent WO2018145525, may treat rheumatoid arthritis.Formule :C25H23N5O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :441.48pan-HER-IN-1
CAS :Compound C5: Irreversible, oral pan-HER inhibitor with low IC50s for EGFR/HERs; induces apoptosis and has antitumor effects.Formule :C19H14BrN5OCouleur et forme :SolidMasse moléculaire :408.25JAK1-IN-4
CAS :JAK1-IN-4 selectively blocks JAK1 (IC50 = 85 nM) over JAK2/JAK3 and halts STAT3 phosphorylation in NCI-H 1975 cells (IC50 = 227 nM).Formule :C26H32FN9O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :521.59Multi-kinase-IN-3
CAS :Multi-kinase-IN-3 (compound 2) is a potent inhibitor of angiokinase and inhibits VEGFR-2 (IC50: 58.3 nM) and PDGFRβ (IC50: 55 nM).Formule :C33H33N5O3Couleur et forme :SolidMasse moléculaire :547.65YF-452
CAS :YF-452 inhibits tumor growth through antiangiogenesis by suppressing VEGF receptor 2 signaling.Formule :C24H26BrN3ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :452.39AAE871
CAS :AAE871 is a type I FLT3 inhibitor.Formule :C24H34N8O2SCouleur et forme :SolidMasse moléculaire :498.64AG-13958 monohydrochloride
CAS :AG-13958 monohydrochloride, a VEGFA inhibitor, may treat neovascular AMD to prevent rapid vision loss.Formule :C26H23ClFN7OCouleur et forme :SolidMasse moléculaire :503.96EGFR/HER2-IN-9
CAS :EGFR/HER2-IN-9, a compound inhibiting both EGFR and HER2, demonstrates potency with IC50 values of 3.2 nM for EGFR, 14 nM for HER2, and 8.3 nM against the EGFRFormule :C25H25ClFN5O4Couleur et forme :SolidMasse moléculaire :513.95KRC-108
CAS :KRC-108 is a potent kinase inhibitor targeting Ron, Flt3, TrkA, and c-Met with strong anti-proliferative effects on various cancer cells.Formule :C20H20N6OCouleur et forme :SolidMasse moléculaire :360.41Ebselen oxide
CAS :Ebselen oxide (EB-2) is a HER2 inhibitor with antibacterial and antifungal activity and has shown cytoprotective effects against HN2 in vitro.Formule :C13H9NO2SeDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :290.18PDGFRα/FLT3-ITD-IN-1
CAS :PDGFRα/FLT3-ITD-IN-1 are potent inhibitors of PDGFRα/FLT3, and their IC50 values are greater than 0.036 and 0.003 μM, respectively.Formule :C27H39N9OCouleur et forme :SolidMasse moléculaire :505.66DPPY
CAS :DPPY inhibits EGFR, BTK, JAK3 (IC50<10 nM), curbs B-cell lymphoma growth, and may be studied for IPF treatment.Formule :C25H26ClN7O3Couleur et forme :SolidMasse moléculaire :507.97FGFR4-IN-5
CAS :FGFR4-IN-5: potent, selective FGFR4 inhibitor, IC50 6.5 nM, strong in vivo anti-tumor effect, for liver cancer research.Formule :C23H23Cl2N5O5Couleur et forme :SolidMasse moléculaire :520.37c-ABL-IN-4
CAS :c-ABL-IN-4 is a potent inhibitor of c-Abl.Formule :C18H11ClF3N3O3Couleur et forme :SolidMasse moléculaire :409.75BAY 2476568
CAS :BAY 2476568 is a selective and potent EGFR inhibitor that acts on both wild-type EGFR (IC50 <0.2 nM) and mutant EGFR (IC50 <0.2 nM).Formule :C24H27FN4O4Couleur et forme :SolidMasse moléculaire :454.49c-ABL-IN-3
CAS :c-ABL-IN-3, from patent WO2021048567A1, is a potent c-Abl inhibitor for researching ALS, PD, and cancer.Formule :C17H11F3N4O3Couleur et forme :SolidMasse moléculaire :376.29EGFR-IN-88
CAS :EGFR-IN-88 (Compound 4i), an EGFR inhibitor with an IC50 of 87 nM, exhibits cytotoxic effects on A549 cells at an IC50 of 3.902 μM and can induce cell apoptosisFormule :C22H18Cl2N4O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :473.37SMU-B
CAS :SMU-B is a well-tolerated c-Met/ALK dual inhibitor.Formule :C26H25Cl2FN4O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :515.41J-1048
CAS :J-1048, an activin receptor-like kinase 5 (ALK5) inhibitor, effectively suppresses TAA-induced liver fibrosis in mice through specific inhibition of the TGF-β/Formule :C23H17FN6S2Couleur et forme :SolidMasse moléculaire :460.55BTK-IN-23
CAS :BTK-IN-23: BTK inhibitor, IC50=12.8 nM; also blocks BLX (35.6 nM), BMX (5.7 nM); better selectivity than Ibrutinib.Formule :C27H28N6O2Couleur et forme :SolidMasse moléculaire :468.55RIPK2-IN-1
CAS :RIPK2-IN-1 (compound 18f) is a potent inhibitor of RIPK2 (IC50: 51 nM) and also inhibits ALK2 (IC50: 5 nM).Formule :C23H27N5O3SCouleur et forme :SolidMasse moléculaire :453.56Flonoltinib
CAS :Flonoltinib (JAK2/FLT3-IN-1) is an orally active and efficient JAK2/FLT3 inhibitor with anti-cancer properties.Formule :C25H34FN7ODegré de pureté :99.52%Couleur et forme :SolidMasse moléculaire :467.58TRK II-IN-1
CAS :TRK II-IN-1: potent type II TRK inhibitor; IC50s: TRKA (3.3 nM), TRKB (6.4 nM), TRKC (4.3 nM), TRKA G667C (9.4 nM); also targets FLT3, RET, VEGFR2.Formule :C29H31F3N8ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :564.6Lavendustin C6
CAS :Lavendustin C6 is a effective tyrosine kinase inhibitor.Formule :C20H25NO5Couleur et forme :SolidMasse moléculaire :359.42HIV-IN-6
CAS :HIV-IN-6, an anti-HIV agent, blocks replication by targeting SFKs like Hck involved with Nef protein.Formule :C20H16N4O3SDegré de pureté :97.78%Couleur et forme :SolidMasse moléculaire :392.43SJF620
CAS :SJF620 is a potent degrader of PROTAC BTK(DC50 : 7.9 nM).Formule :C41H44N8O7Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :760.84Tyk2-IN-7
CAS :Tyk2-IN-7 is an inhibitor of TYK2 JH2, binds to the TYK2 JH2 domain (IC50: 0.00053 μM; Ki.app: 0.00007 μM).Formule :C18H15D3N6O3SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :401.46UNC-CA359
CAS :UNC-CA359: potent EGFR inhibitor, IC50=18 nM, strong anti-tumor effect, promising for chordoma.Formule :C18H14ClN3O2Couleur et forme :SolidMasse moléculaire :339.78MDK5466
CAS :MDK5466 is an Flt3 inhibitor that acts by preventing glutamate-induced cell death.Formule :C21H23N3OSDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :365.49Nazartinib mesylate
CAS :Nazartinib mesylate is a novel, covalent mutant-selective inhibitor of EGFR (Ki and Kinact: 31 nM and 0.222/min on EGFR(L858R/790M) mutant).Formule :C27H35ClN6O5SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :591.12NSC 33994
CAS :NSC 33994 is a selective inhibitor of JAK2 (IC50 = 60 nM). It also shows no effect on Src and TYK2 tyrosine kinase activity at a concentration of 25 μM.Formule :C28H42N2O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :438.65JAK3/BTK-IN-6
CAS :JAK3/BTK-IN-6: potent BTK (0.6 nM) & JAK3 (0.4 nM) inhibitor, stable in human liver, for blood/immune research.Formule :C21H17BF3N5O3Couleur et forme :SolidMasse moléculaire :455.2EGFR-IN-21
CAS :EGFR-IN-21, a potent EGFR inhibitor, exhibits an IC50 of 0.38 nM, demonstrating significant antitumor activity.Formule :C36H44BrN10O2PCouleur et forme :SolidMasse moléculaire :759.68EGFR/CDK2-IN-1
CAS :EGFR/CDK2-IN-1, an inhibitor of both EGFR and CDK2, demonstrates effective cytotoxicity towards MCF7 and HepG2 cells, suggesting its potential application inFormule :C19H12BrClO2Couleur et forme :SolidMasse moléculaire :387.65BCR-ABL-IN-6
CAS :BCR-ABL-IN-6, an imatinib derivative, inhibits Bcr-AblWT (4.6 nM IC50) and T315I (277 nM), for chronic myeloid leukemia study.Formule :C27H22F3N5O2Couleur et forme :SolidMasse moléculaire :505.49VS 8
CAS :VS 8: potent oral VEGFR-2 inhibitor, anti-angiogenic, induces cancer cell apoptosis & migration, acts on CSCs.Formule :C26H20F3N3O3Couleur et forme :SolidMasse moléculaire :479.45EGFR/HER2-IN-2
CAS :EGFR/HER2-IN-2 (Compound ZINC35560729) is a dual EGFR and HER2 inhibitor that acts on both EGFR (IC50: 5.02 μM) and HER2 (IC50: 0.83 μM).Formule :C26H23N5O3Couleur et forme :SolidMasse moléculaire :453.49PP2 Analog
CAS :PP2 Analog is an analog of PP2. It also acts as a protein trafficking modulator.Formule :C16H17ClN4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :300.79Ficonalkib
CAS :Ficonalkib is a potent antineoplastic agent that inhibits the Anaplastic Lymphoma Kinase (ALK) tyrosine kinase receptor.Formule :C29H39N7O3SCouleur et forme :SolidMasse moléculaire :565.73EGFR-IN-46
CAS :EGFR-IN-46: Potent EGFR/FAK inhibitor (IC50: 20.17 & 14.25 nM), curbs cancer cell growth, triggers apoptosis.Formule :C27H32F3N3O3Couleur et forme :SolidMasse moléculaire :503.56JBJ-09-063 hydrochloride
JBJ-09-063 hydrochloride: targeted EGFR inhibitor, effective for various mutations and TKI-resistant lung cancer models.Formule :C31H30ClFN4O3SCouleur et forme :SolidMasse moléculaire :593.11EGFR-IN-25
CAS :EGFR-IN-25, an efficacious EGFR inhibitor, demonstrates IC50 values of 9 nM for BaF3 cells (EGFR DEL19/T790M/C797S) and 60 nM for A431 cells (WT), respectively.Formule :C34H43N9O2Couleur et forme :SolidMasse moléculaire :609.76CP-690550A
CAS :Cp-690550a is a novel JAK3 inhibitor, which is used to treat rheumatoid arthritis, graft rejection, psoriasis, and other immune-mediated diseases.Formule :C15H21N5O2Couleur et forme :SolidMasse moléculaire :303.36EGFR-IN-54
CAS :EGFR-IN-54 (Compound 3c) is a potent inhibitor of EGFR (IC50: 1.623 μM) and is toxic to cancer cells.Formule :C17H14N4O4S3Couleur et forme :SolidMasse moléculaire :434.51NSC114792
CAS :NSC114792 is a selective JAK3 inhibitor.Formule :C26H32N4O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :464.62EGFR-IN-55
CAS :"EGFR-IN-55 targets EGFRWT (70 nM IC50) & EGFRL858R/T790M (3.9 nM IC50), halts NCI-H1975 cell cycle in G0/G1, showing anticancer properties."Formule :C25H25Cl2N7O2Couleur et forme :SolidMasse moléculaire :526.42PD-173956
CAS :PD-173956 is an inhibitor of the Src family tyrosine kinases.Formule :C20H13Cl2FN4OCouleur et forme :SolidMasse moléculaire :415.25EGFR-IN-52
CAS :EGFR-IN-52, a potent EGFR inhibitor, has IC50s: 0.358 μM (wild-type), 86.02 μM (L858R-TK), 432.67 μM (T790M-TK); induces cancer cell apoptosis.Formule :C19H18N4O3SCouleur et forme :SolidMasse moléculaire :382.44XST-14
CAS :XST-14 is a ULK1 inhibitor.XST-14 induces apoptosis and inhibits the growth of HCC cells.Formule :C16H21NO4Degré de pureté :99.84% - 99.84%Couleur et forme :SolidMasse moléculaire :291.34EGFR/HER2/CDK9-IN-3
CAS :EGFR/HER2/CDK9-IN-3 inhibits EGFR (191.08 nM IC50), HER2 (132.65 nM), CDK9 (113.98 nM); shows anti-tumor effects.Formule :C24H21N3O4S2Couleur et forme :SolidMasse moléculaire :479.57SUN13837
CAS :SUN13837, an oral FGFR modulator, crosses the BBB and shows neuroprotective promise.Formule :C21H29N5O2Couleur et forme :SolidMasse moléculaire :383.49Erbstatin
CAS :Erbstatin is a tyrosine-protein kinase inhibitor. When combined with foroxymithine, it has antineoplastic activity against L-1210 leukemia.Formule :C9H9NO3Couleur et forme :SolidMasse moléculaire :179.17TYK2-IN-11
CAS :TYK2-IN-11 (5B) selectively inhibits TYK2 (IC50: 0.016 nM) and JAK1 (IC50: 0.31 nM), aiding autoimmune and inflammatory disease research.Formule :C18H17N5O3SCouleur et forme :SolidMasse moléculaire :383.42EGFR/HER2-IN-3
CAS :EGFR/HER2-IN-3 (Compound ZINC21942954) is a dual EGFR and HER2 inhibitor.Formule :C26H23N5O3Couleur et forme :SolidMasse moléculaire :453.49FLT3-IN-18
CAS :FLT3-IN-18: potent, selective FLT3 inhibitor, IC50 0.003 μM, induces apoptosis, G1 arrest, blocks FLT3/STAT5, potential in AML research.Formule :C26H36N8OCouleur et forme :SolidMasse moléculaire :476.62(R)-Elsubrutinib
CAS :(R)-Elsubrutinib ((R)-ABBV-105) is a Btk inhibitor and an isomer of Elsubrutinib, suitable for inflammation research.Formule :C17H19N3O2Degré de pureté :99.05%Couleur et forme :SolidMasse moléculaire :297.35Ref: TM-T72653
1mg145,00€5mg250,00€10mg340,00€1mL*10mM (DMSO)462,00€25mg573,00€50mg879,00€100mg1.314,00€EGFR-IN-69
CAS :EGFR-IN-69: Potent EGFR inhibitor for NSCLC research; IC50: 4.3-25.6 nM against various EGFR mutations.Formule :C31H37Cl2N7O3SCouleur et forme :SolidMasse moléculaire :658.64TIE-2/VEGFR-2 kinase-IN-1
CAS :TIE-2/VEGFR-2 kinase-IN-1 synthesizes inhibitors for angiogenesis-related disease research.Formule :C13H11N3O2Couleur et forme :SolidMasse moléculaire :241.25VEGFR2 Kinase Inhibitor II
CAS :VEGFR2 kinase inhibitor II: Reversible, cell-permeable, targets VEGFR2 (IC50=70nM), less effective on PDGFRβ (IC50=920nM). Blocks VEGF/PDGF-stimulated growth.Formule :C17H15BrN2OCouleur et forme :SolidMasse moléculaire :343.22EGFR-IN-49
CAS :EGFR-IN-49 selectively inhibits EGFR mutations T790M (IC50: 65 nM) & T790M/L858R (IC50: 13.6 nM), triggering apoptosis dose-dependently.Formule :C22H15N5O2SCouleur et forme :SolidMasse moléculaire :413.45BLK-IN-1
CAS :BLK-IN-1 selectively blocks BLK and BTK with IC50s of 18.8 and 20.5 nM, used in cancer research.Formule :C29H23F3N6O3Couleur et forme :SolidMasse moléculaire :560.53CPL304110
CAS :CPL304110: oral, selective FGFR 1-3 inhibitor; IC50 - FGFR1: 0.75nM, FGFR2: 0.5nM, FGFR3: 3.05nM.Formule :C25H30N6O2Couleur et forme :SolidMasse moléculaire :446.54PHM16
CAS :PHM16 is an ATP competitive FAK and FGFR2 inhibitor.Formule :C20H22N6O4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :410.43EGFR-IN-31
CAS :EGFR-IN-31: Potent EGFR inhibitor, targets mutations & overexpression in NSCLC; potential cancer research compound. (WO2021185298A1, 2)Formule :C32H36FN7O2Couleur et forme :SolidMasse moléculaire :569.67FLT3/D835Y-IN-1
CAS :FLT3/D835Y-IN-1, an oral FLT3 inhibitor (IC50: FLT3 - 0.26 nM, D835Y - 0.18 nM), shows anticancer potential in AML research.Formule :C22H21N5O3Couleur et forme :SolidMasse moléculaire :403.43EGFR-IN-57
CAS :EGFR-IN-57: potent EGFR-TK blocker, IC50 0.054 μM, oral. Halts VEGFR-2, CK2α, topo IIβ, tubulin. Causes G2/M, pre-G1 arrest, cancer cell death.Formule :C22H15N3O2SCouleur et forme :SolidMasse moléculaire :385.44JAK3-IN-1
CAS :JAK3-IN-1 is an orally active, selective and potent JAK3 inhibitor for the study of immune system disorders.Formule :C26H30ClN7O2Couleur et forme :SolidMasse moléculaire :508.02FGFR3-IN-1
CAS :FGFR3-IN-1 (compound 1) is a fibroblast growth factor receptor (FGFR) inhibitor that inhibits FGFR1 (IC50: 40 nM), FGFR2 (IC50: 5.1 nM) and FGFR3 (IC50: 12 nM).Formule :C28H39N9O3SCouleur et forme :SolidMasse moléculaire :581.73TRK/ALK-IN-1
TRK/ALK-IN-1: Potent dual TRK & ALK inhibitor; IC50s: 2.2nM (TRKA), 9.3nM (ALK WT), 38nM (ALK L1196M); cancer research potential.Formule :C31H35ClF2N8O2SCouleur et forme :SolidMasse moléculaire :657.18EGFR-IN-60
CAS :EGFR-IN-60: oral anticancer drug, inhibits EGFR/JAK3, effective on H1975/A431 cells, promotes apoptosis.Formule :C28H28Cl2N6OCouleur et forme :SolidMasse moléculaire :535.47ProMMP-9 inhibitor-3c
CAS :ProMMP-9 inhibitor-3c hinders MMP-9 homodimers, blocks proMMP-9/α4β1 integrin/CD44 binding, and detaches EGFR.Formule :C18H20FN3O2SCouleur et forme :SolidMasse moléculaire :361.43BTK-IN-9
CAS :BTK-IN-9 reversibly inhibits BTK, disrupts mitochondria, boosts ROS, and triggers apoptosis in Z138 cells, impeding condyloma cell growth.Formule :C25H19N7O4Couleur et forme :SolidMasse moléculaire :481.46ZT55
CAS :ZT55: Oral JAK2 inhibitor, IC50: 0.031 μM, hinders JAK2 V617F HEL cell growth, induces apoptosis, arrests cell cycle, effective in mice HEL tumor studies.Formule :C17H16N2O3Couleur et forme :SolidMasse moléculaire :296.32VEGFR-2-IN-24
CAS :VEGFR-2-IN-24 is a potent inhibitor of VEGFR-2 (IC50: 0.22 μM) and can be used to study tumors.Formule :C28H23N3O6SCouleur et forme :SolidMasse moléculaire :529.56FGFR4-IN-11
CAS :FGFR4-IN-11: selective, covalent FGFR4 inhibitor; IC50=2.1 nM; blocks FGF19 pathway; anticancer.Formule :C29H29N5O5Couleur et forme :SolidMasse moléculaire :527.57c-Met-IN-14
CAS :c-Met-IN-14: selective c-Met kinase inhibitor, IC50 2.89 nM, anticancer, stops G2/M phase, induces A549 cell apoptosis.Formule :C34H38ClFN4O7SCouleur et forme :SolidMasse moléculaire :701.2BI-1622
CAS :BI-1622, an oral HER2 inhibitor, IC50: 7 nM, >25x selectivity over EGFR, shows effective in vivo antitumor activity.Formule :C26H24N10O2Couleur et forme :SolidMasse moléculaire :508.53EGFR-IN-26
CAS :EGFR-IN-26 is an EGFR inhibitor that can be used in cancer research.Formule :C29H34N6O3Couleur et forme :SolidMasse moléculaire :514.62ON 146040
CAS :ON 146040 is an effective inhibitor of PI3K isoforms with IC50s of 14 and 20 nM for PI3Kα and PI3Kδ, respectively.Formule :C24H23N7O3SDegré de pureté :97.39%Couleur et forme :SolidMasse moléculaire :489.55Ref: TM-T12310
1mg46,00€5mg96,00€1mL*10mM (DMSO)104,00€10mg156,00€25mg245,00€50mg344,00€100mg460,00€200mg622,00€Antiproliferative agent-20
CAS :Antiproliferative agent-20: potent oral anticancer drug with anti-angiogenic properties.Formule :C23H18N2O6Couleur et forme :SolidMasse moléculaire :418.4Ansornitinib
CAS :Ansornitinib (ANG-3070) is a KDR and PDGF receptor inhibitor with antifibrotic activity for the study of diseases caused by abnormal or excessive fibrosis.Formule :C30H32N6O4Degré de pureté :99.24%Couleur et forme :SolidMasse moléculaire :540.61Atrinositol
CAS :Atrinositol improves energy homeostasis in a mouse model of pancreatic cancer.Formule :C6H15O15P3Couleur et forme :SolidMasse moléculaire :420.1AFG206
CAS :AFG206 is the novel first-generation type II" FLT3 inhibitor."Formule :C20H19N3O2Couleur et forme :SolidMasse moléculaire :333.38ALK-IN-22
CAS :ALK-IN-22 suppresses ALK and mutants (IC50: 2.3-3.7 nM), hinders phosphorylation, and induces apoptosis in tumor studies.Formule :C24H24ClN7O2Couleur et forme :SolidMasse moléculaire :477.95CHMFL-ABL/KIT-155
CAS :CHMFL-ABL/KIT-155 is a highly potent and orally active type II ABL/c-KIT dual kinase inhibitor (IC50s: 46 nM/75 nM).Formule :C33H38F3N5O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :609.68AC710
CAS :AC710 is a potent PDGFR inhibitor (Kds: 0.6, 1, 1.57, 1.3, 1 nM for FLT3, KIT, CSF1R, PDGFRα and PDGFRβ).Formule :C31H42N6O4Degré de pureté :99.67%Couleur et forme :SolidMasse moléculaire :562.7CAY10583
CAS :CAY10583 is a selective BLT2 agonist that increases TGF-β1 and bFGF, promotes keratinocyte migration, accelerates wound healing in diabetic mice.Formule :C25H25NO3Degré de pureté :>99.99% - >99.99%Couleur et forme :SolidMasse moléculaire :387.47EGFR-IN-51
CAS :EGFR-IN-51 effectively inhibits EGFR and mutations with IC50s of 0.493-461.63 μM; it induces apoptosis in cancer cells.Formule :C21H15N3O2SCouleur et forme :SolidMasse moléculaire :373.43JAK-IN-30
CAS :JAK-IN-30 (compound 31) is a water-soluble inhibitor of Janus kinases (JAKs), demonstrating inhibitory potency with half-maximal inhibitory concentration (IC50Formule :C19H26N8SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :398.53
